This Article Full Text Full Text (PDF) Publisher's Note Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyers, P. A. Articles by Grier, H. Search for Related Content PubMed PubMed Citation Articles by Meyers, P. A. Articles by Grier, H. Related Articles Related Correspondence Social Bookmarking                            What's this?

Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate

From the Children's Oncology Group, Arcadia, CA

Address reprint requests to Paul A. Meyers, MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: meyersp{at}mskcc.org

PURPOSE: To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS).

PATIENTS AND METHODS: Six hundred seventy-seven patients with OS without clinically detectable metastatic disease were treated with one of four prospectively randomized treatments. All patients received identical cumulative doses of cisplatin, doxorubicin, and HDMTX and underwent definitive surgical resection of the primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2 x 2 factorial design. The primary end point for analysis was EFS.

RESULTS: Patients treated with the standard arm of therapy had a 3-year EFS of 71%. We could not analyze the results by factorial design because we observed an interaction between the addition of ifosfamide and the addition of MTP. The addition of MTP to standard chemotherapy achieved a 3-year EFS rate of 68%. The addition of ifosfamide to standard chemotherapy achieved a 3-year EFS rate of 61%. The addition of both ifosfamide and MTP resulted in a 3-year EFS rate of 78%.

CONCLUSION: The addition of ifosfamide in this dose schedule to standard chemotherapy did not enhance EFS. The addition of MTP to chemotherapy might improve EFS, but additional clinical and laboratory investigation will be necessary to explain the interaction between ifosfamide and MTP.

A complete listing of grant support for research conducted by the Children's Cancer Group and the Pediatric Oncology Group before initiation of the Children's Oncology Group grant in 2003 is available online at http://www.childrensoncologygroup.org/admin/grantinfo.htm.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Osteosarcoma: The Same Old Drugs or More?
  Stefan S. Bielack, Neyssa Marina, Stefano Ferrari, Lee J. Helman, Sigbjørn Smeland, Jeremy S. Whelan, and Gregory H. Reaman
  JCO 2008 26: 3102-3103 [Full Text]
• Complexities in Interpretation of Osteosarcoma Clinical Trial Results
  Sally Hunsberger, Boris Freidlin, and Malcolm A. Smith
  JCO 2008 26: 3103-3104 [Full Text]

This article has been cited by other articles:

				P. J. Messerschmitt, R. M. Garcia, F. W. Abdul-Karim, E. M. Greenfield, and P. J. Getty Osteosarcoma J. Am. Acad. Ortho. Surg., August 1, 2009; 17(8): 515 - 527. [Abstract] [Full Text] [PDF]

				P. K. Wu, W. M. Chen, C. F. Chen, O. K. Lee, C. K. Haung, and T. H. Chen Primary Osteogenic Sarcoma with Pulmonary Metastasis: Clinical Results and Prognostic Factors in 91 Patients Jpn. J. Clin. Oncol., August 1, 2009; 39(8): 514 - 522. [Abstract] [Full Text] [PDF]

				P. P. Levings, S. V. McGarry, T. P. Currie, D. M. Nickerson, S. McClellan, S. C. Ghivizzani, D. A. Steindler, and C. P. Gibbs Expression of an Exogenous Human Oct-4 Promoter Identifies Tumor-Initiating Cells in Osteosarcoma Cancer Res., July 15, 2009; 69(14): 5648 - 5655. [Abstract] [Full Text] [PDF]

				H. Imran, F. Enders, M. Krailo, F. Sim, S. Okuno, D. Hawkins, J. Neglia, R. L. Randall, R. Womer, L. Mascarenhas, et al. Effect of Time to Resumption of Chemotherapy After Definitive Surgery on Prognosis for Non-Metastatic Osteosarcoma J. Bone Joint Surg. Am., March 1, 2009; 91(3): 604 - 612. [Abstract] [Full Text] [PDF]

				H. Nishida, H. Tsuchiya, and K. Tomita Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma J Bone Joint Surg Br, September 1, 2008; 90-B(9): 1249 - 1255. [Abstract] [Full Text] [PDF]

				S. S. Bielack, N. Marina, S. Ferrari, L. J. Helman, S. Smeland, J. S. Whelan, and G. H. Reaman Osteosarcoma: The Same Old Drugs or More? J. Clin. Oncol., June 20, 2008; 26(18): 3102 - 3103. [Full Text] [PDF]

				S. Hunsberger, B. Freidlin, and M. A. Smith Complexities in Interpretation of Osteosarcoma Clinical Trial Results J. Clin. Oncol., June 20, 2008; 26(18): 3103 - 3104. [Full Text] [PDF]

				C. R. Walkley, R. Qudsi, V. G. Sankaran, J. A. Perry, M. Gostissa, S. I. Roth, S. J. Rodda, E. Snay, P. Dunning, F. H. Fahey, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease Genes & Dev., June 15, 2008; 22(12): 1662 - 1676. [Abstract] [Full Text] [PDF]

				P. A. Meyers, C. L. Schwartz, M. D. Krailo, J. H. Healey, M. L. Bernstein, D. Betcher, W. S. Ferguson, M. C. Gebhardt, A. M. Goorin, M. Harris, et al. Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival--A Report From the Children's Oncology Group J. Clin. Oncol., February 1, 2008; 26(4): 633 - 638. [Abstract] [Full Text] [PDF]

				J. M. Wilmanski, T. Petnicki-Ocwieja, and K. S. Kobayashi NLR proteins: integral members of innate immunity and mediators of inflammatory diseases J. Leukoc. Biol., January 1, 2008; 83(1): 13 - 30. [Abstract] [Full Text] [PDF]

				C. L. Schwartz, R. Gorlick, L. Teot, M. Krailo, A. Goorin, H. E. Grier, M. L. Bernstein, and P. Meyers In Reply J. Clin. Oncol., October 20, 2007; 25(30): 4860 - 4861. [Full Text] [PDF]

				C. L. Schwartz, R. Gorlick, L. Teot, M. Krailo, Z. Chen, A. Goorin, H. E. Grier, M. L. Bernstein, and P. Meyers Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 From the Children's Oncology Group J. Clin. Oncol., May 20, 2007; 25(15): 2057 - 2062. [Abstract] [Full Text] [PDF]

				M. J. Hicks, J. R. Roth, C. A. Kozinetz, and L. L. Wang Clinicopathologic Features of Osteosarcoma in Patients With Rothmund-Thomson Syndrome J. Clin. Oncol., February 1, 2007; 25(4): 370 - 375. [Abstract] [Full Text] [PDF]

				I. J. Lewis, M. A. Nooij, J. Whelan, M. R. Sydes, R. Grimer, P. C. W. Hogendoorn, M. A. Memon, S. Weeden, B. M. Uscinska, M. van Glabbeke, et al. Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup J Natl Cancer Inst, January 17, 2007; 99(2): 112 - 128. [Abstract] [Full Text] [PDF]

				R. S. Kornbluth and G. W. Stone Immunostimulatory combinations: designing the next generation of vaccine adjuvants J. Leukoc. Biol., November 1, 2006; 80(5): 1084 - 1102. [Abstract] [Full Text] [PDF]

				E. Hendershot, A. Pappo, D. Malkin, and L. Sung Tumor Necrosis in Pediatric Osteosarcoma: Impact of Modern Therapies Journal of Pediatric Oncology Nursing, July 1, 2006; 23(4): 176 - 181. [Abstract] [PDF]

				R. L. Vessella, T. A. Guise, E. S. Susman, L. J. Suva, G. A. Clines, S. L. Kominsky, K. L. Weber, J. M. Chirgwin, L. K. McCauley, and W. Kozlow Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA IBMS BoneKEy, March 1, 2006; 3(3): 15 - 42. [Full Text] [PDF]

				A. S. Petrilli, B. de Camargo, V. O. Filho, P. Bruniera, A. L. Brunetto, R. Jesus-Garcia, O. P. Camargo, W. Pena, P. Pericles, A. Davi, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival J. Clin. Oncol., March 1, 2006; 24(7): 1161 - 1168. [Abstract] [Full Text] [PDF]

				J.-L. Romet-Lemonne, B. Mills, W. H. Fridman, and M. Munsell Prospectively Planned Analysis of Data From a Phase III Study of Liposomal Muramyltripeptide Phosphatidylethanolamine in the Treatment of Osteosarcoma J. Clin. Oncol., September 10, 2005; 23(26): 6437 - 6438. [Full Text] [PDF]

				P. A. Meyers, M. Krailo, H. Grier, and M. Bernstein In Reply: J. Clin. Oncol., September 10, 2005; 23(26): 6438 - 6439. [Full Text] [PDF]